Molecular residual disease (MRD) testing is being increasingly utilized in the clinic to detect solid tumor cancer recurrence early and improve patient outcomes. With several assays now on the market and numerous ongoing trials investigating clinical utility, standardized protocols and frameworks for MRD assay validation are vital to ensure that these new tests work as intended and move efficiently through the regulatory approval process. In this webinar, hosted by BLOODPAC member organization Horizon Discovery, Lauren C. Leiman (Executive Director, BLOODPAC) will discuss:

• Progress to date in MRD testing for solid tumors

• Use cases of MRD testing along the cancer patient journey

• The importance of MRD assay analytical validation, including BLOODPAC’s work in creating validation protocols in collaboration with the FDA

• The importance of reference material/contrived materials for assay validation

• Multi-stakeholder collaborative efforts to build consensus on use of reference materials in validation